GlassScriptPhysician profile
Molly D Shields
NPI 1396971255
$1,588.05
in general payments reported to CMS, 2019-2025
27 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $181 · 2022: $504 · 2023: $200 · 2024: $170 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $605.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $295.51 | 2019-2023 | Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $163.99 | 2022 | |
| Sumitomo Pharma America, INC. | $141.99 | 2023-2025 | Myfembree, Gemtesa |
| Avion Pharmaceuticals | $103.09 | 2019-2022 | |
| Organon LLC | $91.65 | 2022-2024 | |
| Shield Therapeutics INC | $83.05 | 2022-2023 | Accrufer |
| Pfizer INC. | $81.15 | 2019-2025 | |
| Biogen, INC. | $80.98 | 2024-2025 | Zurzuvae |
| Astellas Pharma US INC | $78.81 | 2024-2025 | Veozah |
| Millicent US INC | $65.63 | 2019-2025 | Femring, Intrarosa |
| Myovant Sciences INC. | $51.72 | 2022 | |
| Mylan Pharmaceuticals INC. | $47.52 | 2019-2020 | |
| Lupin INC. | $37.31 | 2019-2020 | |
| Acessa Health INC. | $27.62 | 2019 | |
| Therapeuticsmd, INC. | $25.57 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $24.88 | 2025 | Paragard T 380a |
| Medtronic, INC. | $24.73 | 2024 | Truclear |
| Bayer Healthcare Pharmaceuticals INC. | $24.19 | 2020 | |
| Davol INC. | $23.11 | 2024 | Arista Ah Flexitip |
| Exeltis, USA INC. | $19.91 | 2022 | |
| Hologic Sales and Service, LLC | $18.67 | 2019 | |
| Covidien LP | $18.11 | 2020 | |
| Meditrina | $16.88 | 2025 | |
| Agile Therapeutics, INC. | $15.41 | 2022 | |
| Merck Sharp & Dohme LLC | $15.18 | 2020 | |
| Aspira Women'S Health INC | $11.39 | 2024 | Ova1 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Shields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.